BTIG Research Issues Positive Forecast for MDxHealth (NASDAQ:MDXH) Stock Price

MDxHealth (NASDAQ:MDXH) had its target price lifted by BTIG Research from $6.00 to $7.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also recently issued reports on MDXH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. Craig Hallum initiated coverage on MDxHealth in a report on Thursday, July 17th. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, Wall Street Zen upgraded MDxHealth to a “hold” rating in a report on Saturday, August 30th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, MDxHealth currently has an average rating of “Moderate Buy” and an average target price of $7.75.

MDxHealth Price Performance

Shares of MDXH stock traded down $0.33 during mid-day trading on Thursday, reaching $3.64. The company’s stock had a trading volume of 754,621 shares, compared to its average volume of 123,389. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31. The company has a market cap of $172.13 million, a P/E ratio of -4.14 and a beta of 1.68. MDxHealth has a 1-year low of $1.35 and a 1-year high of $5.33. The firm’s 50-day moving average is $4.32 and its two-hundred day moving average is $3.06.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $27.43 million during the quarter, compared to the consensus estimate of $24.11 million. MDxHealth has set its FY 2025 guidance at EPS. On average, research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MDXH. Perkins Capital Management Inc. lifted its holdings in MDxHealth by 20.1% in the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after acquiring an additional 198,000 shares during the last quarter. Delta Investment Management LLC increased its position in shares of MDxHealth by 459.1% in the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock worth $270,000 after acquiring an additional 156,100 shares in the last quarter. AWM Investment Company Inc. increased its holdings in shares of MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock valued at $7,414,000 after purchasing an additional 499,992 shares during the period. FreeGulliver LLC acquired a new position in MDxHealth in the 2nd quarter worth about $273,000. Finally, Calamos Advisors LLC bought a new stake in shares of MDxHealth during the 3rd quarter worth $305,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.